Cargando…
The Atrium in Atrial Fibrillation – A Clinical Review on How to Manage Atrial Fibrotic Substrates
Atrial fibrillation (AF) is the most common sustained arrhythmia in the population and is associated with a significant clinical and economic burden. Rigorous assessment of the presence and degree of an atrial arrhythmic substrate is essential for determining treatment options, predicting long-term...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289204/ https://www.ncbi.nlm.nih.gov/pubmed/35859594 http://dx.doi.org/10.3389/fcvm.2022.879984 |
_version_ | 1784748612183392256 |
---|---|
author | Cunha, Pedro Silva Laranjo, Sérgio Heijman, Jordi Oliveira, Mário Martins |
author_facet | Cunha, Pedro Silva Laranjo, Sérgio Heijman, Jordi Oliveira, Mário Martins |
author_sort | Cunha, Pedro Silva |
collection | PubMed |
description | Atrial fibrillation (AF) is the most common sustained arrhythmia in the population and is associated with a significant clinical and economic burden. Rigorous assessment of the presence and degree of an atrial arrhythmic substrate is essential for determining treatment options, predicting long-term success after catheter ablation, and as a substrate critical in the pathophysiology of atrial thrombogenesis. Catheter ablation of AF has developed into an essential rhythm-control strategy. Nowadays is one of the most common cardiac ablation procedures performed worldwide, with its success inversely related to the extent of atrial structural disease. Although atrial substrate evaluation remains complex, several diagnostic resources allow for a more comprehensive assessment and quantification of the extent of left atrial structural remodeling and the presence of atrial fibrosis. In this review, we summarize the current knowledge on the pathophysiology, etiology, and electrophysiological aspects of atrial substrates promoting the development of AF. We also describe the risk factors for its development and how to diagnose its presence using imaging, electrocardiograms, and electroanatomic voltage mapping. Finally, we discuss recent data regarding fibrosis biomarkers that could help diagnose atrial fibrotic substrates. |
format | Online Article Text |
id | pubmed-9289204 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92892042022-07-19 The Atrium in Atrial Fibrillation – A Clinical Review on How to Manage Atrial Fibrotic Substrates Cunha, Pedro Silva Laranjo, Sérgio Heijman, Jordi Oliveira, Mário Martins Front Cardiovasc Med Cardiovascular Medicine Atrial fibrillation (AF) is the most common sustained arrhythmia in the population and is associated with a significant clinical and economic burden. Rigorous assessment of the presence and degree of an atrial arrhythmic substrate is essential for determining treatment options, predicting long-term success after catheter ablation, and as a substrate critical in the pathophysiology of atrial thrombogenesis. Catheter ablation of AF has developed into an essential rhythm-control strategy. Nowadays is one of the most common cardiac ablation procedures performed worldwide, with its success inversely related to the extent of atrial structural disease. Although atrial substrate evaluation remains complex, several diagnostic resources allow for a more comprehensive assessment and quantification of the extent of left atrial structural remodeling and the presence of atrial fibrosis. In this review, we summarize the current knowledge on the pathophysiology, etiology, and electrophysiological aspects of atrial substrates promoting the development of AF. We also describe the risk factors for its development and how to diagnose its presence using imaging, electrocardiograms, and electroanatomic voltage mapping. Finally, we discuss recent data regarding fibrosis biomarkers that could help diagnose atrial fibrotic substrates. Frontiers Media S.A. 2022-07-04 /pmc/articles/PMC9289204/ /pubmed/35859594 http://dx.doi.org/10.3389/fcvm.2022.879984 Text en Copyright © 2022 Cunha, Laranjo, Heijman and Oliveira. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Cunha, Pedro Silva Laranjo, Sérgio Heijman, Jordi Oliveira, Mário Martins The Atrium in Atrial Fibrillation – A Clinical Review on How to Manage Atrial Fibrotic Substrates |
title | The Atrium in Atrial Fibrillation – A Clinical Review on How to Manage Atrial Fibrotic Substrates |
title_full | The Atrium in Atrial Fibrillation – A Clinical Review on How to Manage Atrial Fibrotic Substrates |
title_fullStr | The Atrium in Atrial Fibrillation – A Clinical Review on How to Manage Atrial Fibrotic Substrates |
title_full_unstemmed | The Atrium in Atrial Fibrillation – A Clinical Review on How to Manage Atrial Fibrotic Substrates |
title_short | The Atrium in Atrial Fibrillation – A Clinical Review on How to Manage Atrial Fibrotic Substrates |
title_sort | atrium in atrial fibrillation – a clinical review on how to manage atrial fibrotic substrates |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289204/ https://www.ncbi.nlm.nih.gov/pubmed/35859594 http://dx.doi.org/10.3389/fcvm.2022.879984 |
work_keys_str_mv | AT cunhapedrosilva theatriuminatrialfibrillationaclinicalreviewonhowtomanageatrialfibroticsubstrates AT laranjosergio theatriuminatrialfibrillationaclinicalreviewonhowtomanageatrialfibroticsubstrates AT heijmanjordi theatriuminatrialfibrillationaclinicalreviewonhowtomanageatrialfibroticsubstrates AT oliveiramariomartins theatriuminatrialfibrillationaclinicalreviewonhowtomanageatrialfibroticsubstrates AT cunhapedrosilva atriuminatrialfibrillationaclinicalreviewonhowtomanageatrialfibroticsubstrates AT laranjosergio atriuminatrialfibrillationaclinicalreviewonhowtomanageatrialfibroticsubstrates AT heijmanjordi atriuminatrialfibrillationaclinicalreviewonhowtomanageatrialfibroticsubstrates AT oliveiramariomartins atriuminatrialfibrillationaclinicalreviewonhowtomanageatrialfibroticsubstrates |